No Cover Image

Journal article 714 views

P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries

Uwe Zeymer, Petr Widimsky, Nicolas Danchin, Maddalena Lettino, Alfredo Bardaji, Jose A. Barrabes, Angel Cequier, Marc J. Claeys, Leonardo De Luca, Jakob Dörler, David Erlinge, Paul Erne, Patrick Goldstein, Sasha M. Koul, Gilles Lemesle, Thomas F. Lüscher, Christian M. Matter, Gilles Montalescot, Dragana Radovanovic, Jose Lopez Sendón, Petr Tousek, Franz Weidinger, Clive Weston Orcid Logo, Azfar Zaman, Pontus Andell, Jin Li, J. Wouter Jukema

European Heart Journal - Cardiovascular Pharmacotherapy, Volume: 2, Issue: 4, Pages: 229 - 243

Swansea University Author: Clive Weston Orcid Logo

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1093/ehjcvp/pvw005

Abstract

Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70% of patients admitted with ACS. This study provides a ‘real-life’ overview of NSTE-ACS patient characteristics, dual antiplatelet therapy, and outcomes at both the time of discharge from hospital and up to 1-year post-disc...

Full description

Published in: European Heart Journal - Cardiovascular Pharmacotherapy
ISSN: 2055-6837 2055-6845
Published: 2016
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa31533
Tags: Add Tag
No Tags, Be the first to tag this record!
first_indexed 2016-12-30T20:55:13Z
last_indexed 2018-02-09T05:18:33Z
id cronfa31533
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2017-02-07T14:51:08.7924022</datestamp><bib-version>v2</bib-version><id>31533</id><entry>2016-12-30</entry><title>P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries</title><swanseaauthors><author><sid>df85e4e0e139d0f46eb683174eba98a9</sid><ORCID>0000-0002-8995-8199</ORCID><firstname>Clive</firstname><surname>Weston</surname><name>Clive Weston</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2016-12-30</date><deptcode>PMSC</deptcode><abstract>Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60&#x2013;70% of patients admitted with ACS. This study provides a &#x2018;real-life&#x2019; overview of NSTE-ACS patient characteristics, dual antiplatelet therapy, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge.10 registries (including 84 054 NSTE-ACS patients) provided data on patient characteristics and outcomes, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry).Conclusions There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events.</abstract><type>Journal Article</type><journal>European Heart Journal - Cardiovascular Pharmacotherapy</journal><volume>2</volume><journalNumber>4</journalNumber><paginationStart>229</paginationStart><paginationEnd>243</paginationEnd><publisher/><issnPrint>2055-6837</issnPrint><issnElectronic>2055-6845</issnElectronic><keywords>Acute coronary syndrome, myocardial infarction, anti-platelet, registry</keywords><publishedDay>1</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2016</publishedYear><publishedDate>2016-10-01</publishedDate><doi>10.1093/ehjcvp/pvw005</doi><url/><notes/><college>COLLEGE NANME</college><department>Medicine</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>PMSC</DepartmentCode><institution>Swansea University</institution><apcterm/><lastEdited>2017-02-07T14:51:08.7924022</lastEdited><Created>2016-12-30T16:18:11.5872699</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Uwe</firstname><surname>Zeymer</surname><order>1</order></author><author><firstname>Petr</firstname><surname>Widimsky</surname><order>2</order></author><author><firstname>Nicolas</firstname><surname>Danchin</surname><order>3</order></author><author><firstname>Maddalena</firstname><surname>Lettino</surname><order>4</order></author><author><firstname>Alfredo</firstname><surname>Bardaji</surname><order>5</order></author><author><firstname>Jose A.</firstname><surname>Barrabes</surname><order>6</order></author><author><firstname>Angel</firstname><surname>Cequier</surname><order>7</order></author><author><firstname>Marc J.</firstname><surname>Claeys</surname><order>8</order></author><author><firstname>Leonardo</firstname><surname>De Luca</surname><order>9</order></author><author><firstname>Jakob</firstname><surname>D&#xF6;rler</surname><order>10</order></author><author><firstname>David</firstname><surname>Erlinge</surname><order>11</order></author><author><firstname>Paul</firstname><surname>Erne</surname><order>12</order></author><author><firstname>Patrick</firstname><surname>Goldstein</surname><order>13</order></author><author><firstname>Sasha M.</firstname><surname>Koul</surname><order>14</order></author><author><firstname>Gilles</firstname><surname>Lemesle</surname><order>15</order></author><author><firstname>Thomas F.</firstname><surname>L&#xFC;scher</surname><order>16</order></author><author><firstname>Christian M.</firstname><surname>Matter</surname><order>17</order></author><author><firstname>Gilles</firstname><surname>Montalescot</surname><order>18</order></author><author><firstname>Dragana</firstname><surname>Radovanovic</surname><order>19</order></author><author><firstname>Jose Lopez</firstname><surname>Send&#xF3;n</surname><order>20</order></author><author><firstname>Petr</firstname><surname>Tousek</surname><order>21</order></author><author><firstname>Franz</firstname><surname>Weidinger</surname><order>22</order></author><author><firstname>Clive</firstname><surname>Weston</surname><orcid>0000-0002-8995-8199</orcid><order>23</order></author><author><firstname>Azfar</firstname><surname>Zaman</surname><order>24</order></author><author><firstname>Pontus</firstname><surname>Andell</surname><order>25</order></author><author><firstname>Jin</firstname><surname>Li</surname><order>26</order></author><author><firstname>J. Wouter</firstname><surname>Jukema</surname><order>27</order></author></authors><documents/><OutputDurs/></rfc1807>
spelling 2017-02-07T14:51:08.7924022 v2 31533 2016-12-30 P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries df85e4e0e139d0f46eb683174eba98a9 0000-0002-8995-8199 Clive Weston Clive Weston true false 2016-12-30 PMSC Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70% of patients admitted with ACS. This study provides a ‘real-life’ overview of NSTE-ACS patient characteristics, dual antiplatelet therapy, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge.10 registries (including 84 054 NSTE-ACS patients) provided data on patient characteristics and outcomes, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry).Conclusions There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events. Journal Article European Heart Journal - Cardiovascular Pharmacotherapy 2 4 229 243 2055-6837 2055-6845 Acute coronary syndrome, myocardial infarction, anti-platelet, registry 1 10 2016 2016-10-01 10.1093/ehjcvp/pvw005 COLLEGE NANME Medicine COLLEGE CODE PMSC Swansea University 2017-02-07T14:51:08.7924022 2016-12-30T16:18:11.5872699 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Uwe Zeymer 1 Petr Widimsky 2 Nicolas Danchin 3 Maddalena Lettino 4 Alfredo Bardaji 5 Jose A. Barrabes 6 Angel Cequier 7 Marc J. Claeys 8 Leonardo De Luca 9 Jakob Dörler 10 David Erlinge 11 Paul Erne 12 Patrick Goldstein 13 Sasha M. Koul 14 Gilles Lemesle 15 Thomas F. Lüscher 16 Christian M. Matter 17 Gilles Montalescot 18 Dragana Radovanovic 19 Jose Lopez Sendón 20 Petr Tousek 21 Franz Weidinger 22 Clive Weston 0000-0002-8995-8199 23 Azfar Zaman 24 Pontus Andell 25 Jin Li 26 J. Wouter Jukema 27
title P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
spellingShingle P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
Clive Weston
title_short P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
title_full P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
title_fullStr P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
title_full_unstemmed P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
title_sort P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries
author_id_str_mv df85e4e0e139d0f46eb683174eba98a9
author_id_fullname_str_mv df85e4e0e139d0f46eb683174eba98a9_***_Clive Weston
author Clive Weston
author2 Uwe Zeymer
Petr Widimsky
Nicolas Danchin
Maddalena Lettino
Alfredo Bardaji
Jose A. Barrabes
Angel Cequier
Marc J. Claeys
Leonardo De Luca
Jakob Dörler
David Erlinge
Paul Erne
Patrick Goldstein
Sasha M. Koul
Gilles Lemesle
Thomas F. Lüscher
Christian M. Matter
Gilles Montalescot
Dragana Radovanovic
Jose Lopez Sendón
Petr Tousek
Franz Weidinger
Clive Weston
Azfar Zaman
Pontus Andell
Jin Li
J. Wouter Jukema
format Journal article
container_title European Heart Journal - Cardiovascular Pharmacotherapy
container_volume 2
container_issue 4
container_start_page 229
publishDate 2016
institution Swansea University
issn 2055-6837
2055-6845
doi_str_mv 10.1093/ehjcvp/pvw005
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 0
active_str 0
description Non-ST-elevation acute coronary syndrome (NSTE-ACS) is present in about 60–70% of patients admitted with ACS. This study provides a ‘real-life’ overview of NSTE-ACS patient characteristics, dual antiplatelet therapy, and outcomes at both the time of discharge from hospital and up to 1-year post-discharge.10 registries (including 84 054 NSTE-ACS patients) provided data on patient characteristics and outcomes, and 6 of these (with 52 173 NSTE-ACS patients) also provided more specific data according to P2Y12 receptor inhibitor used. Unadjusted analyses were performed at the study level, and no formal meta-analysis was performed due to large heterogeneity between studies in the settings, patient characteristics, and outcome definitions. All-cause death rates across registries ranged from 0.76 to 4.79% in-hospital, from 1.61 to 6.65% at 30 days, from 3.66 to 7.16% at 180 days, and from 3.14 to 9.73% at 1 year. Major bleeding events were reported in up to 2.77% of patients while in hospital (in seven registries), up to 1.08% at 30 days (data from one registry only), and 2.06% at 1 year (one registry).Conclusions There were substantial differences in the use of and patient selection for clopidogrel, prasugrel, and ticagrelor, which were associated with differences in short- and long-term ischaemic and bleeding events.
published_date 2016-10-01T03:38:32Z
_version_ 1763751716972396544
score 11.012678

Similar Items